Committed to Medical Innovations
Every day—in research labs across eastern Massachusetts—investigators, doctors and nurses at Partners HealthCare are working to discover new treatment options, medical devices and technology to improve the lives and outcomes of patients. Partners HealthCare Innovation works directly with researchers at Brigham and Women’s Hospital, Massachusetts General Hospital, McLean Hospital and Spaulding Hospital to commercialize their innovations. It is our mission to enable commercialization through the best route for a given technology, and ensure that technologies can benefit patients.
Lyndra Inc. and Global Drug Commercialization Center Announce Joint Venture to Develop Lyndra’s Ultra-long-acting Oral Dosage Form for Chinese Market
Lyndra Inc., an emerging biopharmaceutical company, today announced the formation of a joint venture with Global Drug Commercialization Center (GDCC) to commercialize Lyndra’s groundbreaking medicines in China. The partners held a public ribbon-cutting ceremony for the new Lyndra (China) Pharmaceuticals Co., Ltd. headquarters in Chengdu, China. Lyndra is developing ultra-long-acting oral therapies that free patients…Read More
The 2018 World Medical Innovation Forum focuses on the advancements and opportunities of Artificial Intelligence. The event will bring together industry-leading CEOs, Partners' HIT experts, investors and deal makers to share perspectives on how cognitive computation, machine learning, and big date are having a transformative impact on patient care.
Innovation Symposium Series
The Innovation Symposium Series is a five-part speaker series focused on navigating the innovation lifecycle. The Symposium Series is a complimentary, invitation-only gathering that encourages innovation and recognizes the entrepreneurial spirit of our research community. It is open to any PHS-affiliated investigator, clinician and administrator working on, or considering, research that will enhance the care continuum, improve the patient experience and increase positive outcomes. Attendees will hear from Innovation staff, HIT experts, investors and deal-makers from industry, venture, government and academia.